--- title: 'Industry Daily Summary: What Happened on November 4, 2026' headline: Processa buys Vidya, adds $200 million in financing description: The deal brings Vidya’s BTK inhibitor pipeline into Processa. GEBRO and Spektus also struck a global pain-drug partnership, while AbbVie invested in a UK expansion. url: https://thebench.bio/news/industry/2026-11-04 topic: industry date: '2026-11-04' covers: - '2026-11-04' date_published: '2026-11-04T12:03:13Z' date_modified: '2026-11-04T12:03:13Z' tags: - Industry - Funding sources: 3 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on November 4, 2026 **Processa buys Vidya, adds $200 million in financing** The deal brings Vidya’s BTK inhibitor pipeline into Processa. GEBRO and Spektus also struck a global pain-drug partnership, while AbbVie invested in a UK expansion. ## Today in brief Processa acquired Vidya Therapeutics and secured $200 million in PIPE financing for the combined company, with Sheila Gujrathi as executive chair. [1] The combined company is developing Vidya’s BTK inhibitor VT-7208 for food allergies, chronic spontaneous urticaria and relapsing multiple sclerosis. [1] ## Processa acquires Vidya and backs the combined company with $200 million Processa acquired Vidya Therapeutics, with Sheila Gujrathi taking the role of executive chair at the combined company. [1] The company has $200 million in PIPE financing and is developing Vidya’s BTK inhibitor VT-7208 for food allergies, chronic spontaneous urticaria and relapsing multiple sclerosis. [1] Gujrathi previously served as Receptos’ chief medical officer, co-founded Gossamer Bio and was a co-founding chief financial officer of Prana Therapies. [1] Celgene acquired Receptos for $7.2 billion. Bolt Biotherapeutics acquired Prana last month, and Gujrathi became Bolt’s chief strategy officer. [1] ## Also worth knowing - GEBRO Holding and Spektus Pharma agreed to commercialize ActraFlex globally. GEBRO will handle Europe and certain other markets, while Spektus will cover Africa, the Americas and Asia through regional partners. [2] - ActraFlex combines paracetamol and tramadol in an extended-release formulation designed for twice-daily use. [2] - AbbVie invested £120 million in a UK expansion. [3] ## The day in numbers - **$200 million**: PIPE financing for the combined Processa-Vidya company. [1] - **£120 million**: AbbVie’s investment in its UK expansion. [3] - **$7.2 billion**: Celgene’s purchase price for Receptos, where Sheila Gujrathi previously served as chief medical officer. [1] ## Also published - [ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal](), Applied Clinical Trials ## Sources 1. [With Vidya acquisition, Gujrathi takes chair role at Processa](), BioCentury, 2026-11-04 2. [GEBRO and Spektus sign collaboration for ActraFlex](), Pharmaceutical Technology, 2026-11-04 3. [AbbVie invests £120m in UK expansion](), pharmaphorum, 2026-11-04 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: